Private Companies Who Have a Significant Stake Must Be Disappointed Along With Institutions After Luye Pharma Group Ltd.'s (HKG:2186) Market Cap Dropped by HK$940m
Key Insights Significant control over Luye Pharma Group by private companies implies that the general public has more power to influence management and governance-related decisions 56% of the busine
Luye Pharma Group Ltd. (HKG:2186) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 17.8x Luye Pharma Group Ltd. (HKG:2186) may be sending very bearish signals at the moment, given that almost half of all companies in Hong Kong have P/E ra
Is There An Opportunity With Luye Pharma Group Ltd.'s (HKG:2186) 27% Undervaluation?
Key Insights The projected fair value for Luye Pharma Group is HK$3.88 based on 2 Stage Free Cash Flow to Equity Luye Pharma Group is estimated to be 27% undervalued based on current share price of
Global Transdermal Medical Patch Market Analysis 2024-2029, Featuring Novartis, Viatris, Nitto Denko, Luye Pharma, Hisamitsu Pharmaceutical, Medline Industries, Corium, UCB, Teikoku Pharma and More
DUBLIN, March 25, 2024 /PRNewswire/ -- The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been adde
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%
Luye Pharma Group's (HKG:2186) LY03010 injectable for schizophrenia and schizoaffective disorder overcame patent challenges during the new drug application review process by the US Food and Drug Admin
Luye Pharma Group (HKG:2186) Stock Falls 4.7% in Past Week as Three-year Earnings and Shareholder Returns Continue Downward Trend
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been particularly tough on longer term Luye Pharma Group Ltd. (HKG:2186) shareholder
What Luye Pharma Group Ltd.'s (HKG:2186) P/S Is Not Telling You
There wouldn't be many who think Luye Pharma Group Ltd.'s (HKG:2186) price-to-sales (or "P/S") ratio of 1.8x is worth a mention when the median P/S for the Pharmaceuticals industry in Hong Kong is sim
Is Luye Pharma Group (HKG:2186) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval
Hong Kong's pharmacy and poisons board approved Luye Pharma's (HKG:2186) marketing application for lurbinectedin intended to treat metastatic small cell lung cancer, a Wednesday filing said. Mainland
Calculating The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)
Key Insights The projected fair value for Luye Pharma Group is HK$3.77 based on 2 Stage Free Cash Flow to Equity With HK$3.98 share price, Luye Pharma Group appears to be trading close to its estima
Schizoaffective Disorder Drug Pipeline Research Report 2023 Featuring Lyndra Therapeutics, Luye Pharma Group, BioXcel Therapeutics, & Reviva Pharma - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Schizoaffective Disorder - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.The "Schizoaffective Disorder - Pipeline Insight, 2
Despite Shrinking by HK$489m in the Past Week, Luye Pharma Group (HKG:2186) Shareholders Are Still up 62% Over 1 Year
The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you could make more than that. To wit, the Luye Pharma Group Ltd. (HKG:2186) share
Luye Pharma Files New Drug Application in US for Schizophrenia Medication
Luye Pharma Group (HKG:2186) submitted a new drug application to the US Food and Drug Administration for LY03010 as a treatment for schizophrenia and schizoaffective disorder. LY03010 "is expected to
Luye Pharma Group Ltd. (HKG:2186) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Luye Pharma Group's (HKG:2186) stock is up by a considerable 19% over the past month. However, we wonder if the company's inconsistent financials would have any adverse impact on the current share p
Luye Pharma Group (HKG:2186) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
China Approves Luye Pharma's Breast Cancer Injectable
China's medical products administrator approved Luye Pharma Group's (HKG:2186) injectable for breast cancer treatment in premenopausal and perimenopausal women, according to a Thursday filing. The dru
Luye Pharma's Rykindo Enters US Market; Shares Down 3%
Luye Pharma Group's (HKG:2186) drug, Rykindo, officially entered the US market after the company shipped the first batch of the drug overseas, the Hong Kong-listed pharmaceutical company said in its T
Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price
Key Insights The projected fair value for Luye Pharma Group is HK$2.47 based on 2 Stage Free Cash Flow to Equity Current share price of HK$3.09 suggests Luye Pharma Group is potentially 25% overvalu
Luye Pharma Group Ltd.'s (HKG:2186) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 3.1% Last Week
Key Insights Significant control over Luye Pharma Group by retail investors implies that the general public has more power to influence management and governance-related decisions A total of 3 inves
Luye Pharma Completes Patient Enrollment for Phase 2 Trial of Post-Operative Pain Drug; Shares Rise 5%
Luye Pharma Group (HKG:2186) completed patient enrollment for the phase 2 clinical trial of its LY03014 treatment for severe acute postoperative pain and breakthrough cancer pain, a Thursday filing sa
No Data